Recent Quotes

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-03
REV		(EXPECTED)2021-08-03

Q1 2021		Est.		Actual		Surprise
EPS		-1.910		-1.640		0.2700
REV		2.000M		1.583M		-417.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
SAGE	Sage Therapeutics	44.83	1.50	3.46%		2.6B

Sage Therapeutics Frequently Asked Questions

How do I buy Sage Therapeutics (SAGE) stock?

You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.

View our list of the best stock brokerages.

Who are Sage Therapeutics's (SAGE) competitors?

Other companies in Sage Therapeutics’s space includes: Zentalis Pharmaceuticals (NASDAQ:ZNTL), Karuna Therapeutics (NASDAQ:KRTX), OPKO Health (NASDAQ:OPK), PTC Therapeutics (NASDAQ:PTCT) and Agios Pharmaceuticals (NASDAQ:AGIO).

What is the target price for Sage Therapeutics (SAGE) stock?

The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by Canaccord Genuity on July 27, 2021. The analyst firm set a price target for 96.00 expecting SAGE to rise to within 12 months (a possible 114.14% upside). 25 analyst firms have reported ratings in the last year.

Current Stock Price for Sage Therapeutics (SAGE)?

The stock price for Sage Therapeutics (NASDAQ: SAGE) is $44.83 last updated Today at 7:18:24 PM.

Does Sage Therapeutics (SAGE) pay a dividend?

There are no upcoming dividends for Sage Therapeutics.

When is Sage Therapeutics (NASDAQ:SAGE) reporting earnings?

Sage Therapeutics’s Q2 earnings are confirmed for after-market on August 3, 2021.

Is Sage Therapeutics (SAGE) going to split?

There is no upcoming split for Sage Therapeutics.

What sector and industry does Sage Therapeutics (SAGE) operate in?

Sage Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.